148 related articles for article (PubMed ID: 24575881)
1. Lichen planopilaris after imiquimod 5% cream for multiple BCC in basal cell naevus syndrome.
Drummond A; Pichler J; Argenziano G; Zalaudek I; Longo C; Lallas A; Piana S; Moscarella E
Australas J Dermatol; 2015 Nov; 56(4):e105-7. PubMed ID: 24575881
[TBL] [Abstract][Full Text] [Related]
2. Successful treatment of basal cell carcinomas in a nevoid basal cell carcinoma syndrome with topical 5% imiquimod.
Stockfleth E; Ulrich C; Hauschild A; Lischner S; Meyer T; Christophers E
Eur J Dermatol; 2002; 12(6):569-72. PubMed ID: 12459530
[TBL] [Abstract][Full Text] [Related]
3. Hundreds of basal cell carcinomas in a Gorlin-Goltz syndrome patient cured with imiquimod 5% cream.
Ferreres JR; Macaya A; Jucglà A; Muniesa C; Prats C; Peyrí J
J Eur Acad Dermatol Venereol; 2006 Aug; 20(7):877-8. PubMed ID: 16898919
[No Abstract] [Full Text] [Related]
4. Generalized exacerbation of psoriasis associated with imiquimod cream treatment of superficial basal cell carcinomas.
Rajan N; Langtry JA
Clin Exp Dermatol; 2006 Jan; 31(1):140-1. PubMed ID: 16309513
[No Abstract] [Full Text] [Related]
5. Successful treatment of multifocal pigmented basal cell carcinomas with the application of topical 5% imiquimod cream.
Plachouri KM; Balasis S; Mallioris AF; Koumoundourou D; Georgiou S
Dermatol Ther; 2018 Sep; 31(5):e12685. PubMed ID: 30133929
[TBL] [Abstract][Full Text] [Related]
6. The use of imiquimod 5% cream for the treatment of basal cell carcinoma as observed in Gorlin's syndrome.
Micali G; Lacarrubba F; Nasca MR; De Pasquale R
Clin Exp Dermatol; 2003 Nov; 28 Suppl 1():19-23. PubMed ID: 14616807
[TBL] [Abstract][Full Text] [Related]
7. The use of imiquimod 5% cream for the treatment of superficial basal cell carcinomas in a basal cell nevus syndrome patient.
Kagy MK; Amonette R
Dermatol Surg; 2000 Jun; 26(6):577-8; discussion 578-9. PubMed ID: 10848940
[TBL] [Abstract][Full Text] [Related]
8. Topical imiquimod treatment of superficial and nodular basal cell carcinomas in patients affected by basal cell nevus syndrome: a preliminary report.
Micali G; De Pasquale R; Caltabiano R; Impallomeni R; Lacarrubba F
J Dermatolog Treat; 2002 Sep; 13(3):123-7. PubMed ID: 12227875
[TBL] [Abstract][Full Text] [Related]
9. Imiquimod 5% cream (Aldara) in the treatment of basal cell carcinoma.
Sapijaszko MJ
Skin Therapy Lett; 2005; 10(6):2-5. PubMed ID: 16292452
[TBL] [Abstract][Full Text] [Related]
10. Pemphigus-like lesions induced by imiquimod.
Bauza A; Del Pozo LJ; Saus C; Martin A
Clin Exp Dermatol; 2009 Jul; 34(5):e60-2. PubMed ID: 19438577
[TBL] [Abstract][Full Text] [Related]
11. Open study of the efficacy and mechanism of action of topical imiquimod in basal cell carcinoma.
Vidal D; Matías-Guiu X; Alomar A
Clin Exp Dermatol; 2004 Sep; 29(5):518-25. PubMed ID: 15347339
[TBL] [Abstract][Full Text] [Related]
12. Complete basal cell carcinoma remission with imiquimod in a patient with nevoid basal cell carcinoma syndrome and associated basal cell carcinoma of the scalp and invasive ductal breast cancer.
Quist SR; Franke I; Helmdach M; Kraus C; Reis A; Froster UG; Fehsecke D; Gollnick HP; Bonnekoh B
J Am Acad Dermatol; 2011 Mar; 64(3):611-3. PubMed ID: 21315966
[No Abstract] [Full Text] [Related]
13. Electrochemotherapy: a valid treatment for Gorlin-Goltz syndrome.
Curatolo P; Miraglia E; Rotunno R; Calvieri S; Giustini S
Acta Dermatovenerol Croat; 2013; 21(2):132-3. PubMed ID: 24001423
[No Abstract] [Full Text] [Related]
14. Imiquimod: a review of basal cell carcinoma treatments.
Karve SJ; Feldman SR; Yentzer BA; Pearce DJ; Balkrishnan R
J Drugs Dermatol; 2008 Nov; 7(11):1044-51. PubMed ID: 19110735
[TBL] [Abstract][Full Text] [Related]
15. Giant basal cell carcinoma. Improvement and vitiligo-like hypopigmentation after intermittent treatment with 5% imiquimod.
Urbina F
Acta Dermatovenerol Croat; 2012; 20(4):275-8. PubMed ID: 23317492
[No Abstract] [Full Text] [Related]
16. Imiquimod 5% cream for the treatment of superficial basal cell carcinoma: results from a randomized vehicle-controlled phase III study in Europe.
Schulze HJ; Cribier B; Requena L; Reifenberger J; Ferrándiz C; Garcia Diez A; Tebbs V; McRae S
Br J Dermatol; 2005 May; 152(5):939-47. PubMed ID: 15888150
[TBL] [Abstract][Full Text] [Related]
17. Squamous cell carcinoma on the scalp following treatment with 5% imiquimod cream.
Singh S; Bunker CB
Clin Exp Dermatol; 2007 Sep; 32(5):594-5. PubMed ID: 17692065
[No Abstract] [Full Text] [Related]
18. Vasodilatory adverse events associated with topical imiquimod 5 percent cream.
Jacobs AA; Snavely N; Markus J; Rosen T
Dermatol Online J; 2008 Apr; 14(4):4. PubMed ID: 18627726
[TBL] [Abstract][Full Text] [Related]
19. Vitiligo-like depigmentation induced by imiquimod treatment of superficial basal cell carcinoma.
Sriprakash K; Godbolt A
Australas J Dermatol; 2009 Aug; 50(3):211-3. PubMed ID: 19659986
[TBL] [Abstract][Full Text] [Related]
20. Topical imiquimod therapy for basal and squamous cell carcinomas: a clinical experience.
Tillman DK; Carroll MT
Cutis; 2007 Mar; 79(3):241-8. PubMed ID: 17674590
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
